By Fineline Cube 
China-based Jiangsu Wuzhong Pharmaceutical Group Corp. (SHA: 600200) has disclosed a potential forced delisting from the Shanghai Stock Exchange following an investigation by the China Securities Regulatory Commission (CSRC). The company’s filing indicates that mandatory delisting procedures will be initiated if regulators confirm significant violations of listing rules.
Background of the Investigation
The risk of delisting stems from a March 2025 disclosure revealing that Wuzhong Pharma’s subsidiary, Jiangsu Wuzhong Import & Export Co., Ltd., and former chairman Yang Feng, were charged with criminal liability for aiding Lin Xiqin and others in a RMB 242 million (USD 33 million) export tax fraud scheme. The illicit gains from the scheme reportedly exceeded RMB 16 million (USD 2.2 million). As of the latest update, the trial for this case has not yet commenced.
Market and Regulatory Impact
The potential delisting highlights the serious consequences of regulatory non-compliance and underscores the CSRC’s efforts to enforce listing rules and maintain market integrity. Investors and stakeholders are advised to monitor developments closely as the investigation progresses.-Fineline Info & Tech